Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of lopinavir/ritonavir in castration-resistant prostate cancer
ChiCTR2400089169Phase 2Not yet recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lopinavir + ritonavir in prostate cancer (PCa), sponsored by Xiangya Hospital, Central South University. Primary endpoint: PSA assessment. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
lopinavir + ritonavir
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2400089169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089169.